-
Subject Areas on Research
-
A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
-
Are sulfonylureas passé?
-
Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study.
-
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.
-
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
-
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
-
Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas.
-
Cryptococcus neoformans Ilv2p confers resistance to sulfometuron methyl and is required for survival at 37 degrees C and in vivo.
-
Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes.
-
Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
-
Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
-
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
-
Growth inhibition of pathogenic bacteria by sulfonylurea herbicides.
-
Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015.
-
Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.
-
Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
-
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
-
Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
-
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
-
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
-
Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction.
-
Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
-
Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.